Search

Your search keyword '"Lon S Schneider"' showing total 533 results

Search Constraints

Start Over You searched for: Author "Lon S Schneider" Remove constraint Author: "Lon S Schneider"
533 results on '"Lon S Schneider"'

Search Results

1. Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time.

2. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

3. A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

4. The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States

5. Reliability of the NACC Telephone‐administered Neuropsychological Battery (T‐cog) and Montreal Cognitive Assessment for participants in the USC ADRC

6. Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment

7. Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

8. Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes

9. The efficacy of antidepressant medication and interpersonal psychotherapy for adult acute-phase depression: study protocol of a systematic review and meta-analysis of individual participant data

10. The small HDL particle hypothesis of Alzheimer's disease

11. New insights into the genetic etiology of Alzheimer's disease and related dementias

12. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

13. The need to show minimum clinically important differences in Alzheimer's disease trials

14. Cognitive Correlates of the No Practice Effects (NPE) Battery: Factor Analyses from the Novel Cognitive and Functional Measures for Alzheimer’s Disease Prevention Trials (NoMAD)

15. Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 2 proof‐of‐concept clinical trial using hippocampal volume as a surrogate endpoint

16. The regional relationship between CSF VEGF and white matter microstructural integrity in older adults: A voxelwise DTI study

17. Diversity in Alzheimer’s Disease drug trials: The importance of eligibility criteria

18. Evaluation of the performance of alternative models in analyzing longitudinal data for Alzheimer clinical trials compared to MMRM

19. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

20. Corrigendum: Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images

21. Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group

22. The Current Landscape of Prevention Trials in Dementia

23. Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid

24. Progression of Alzheimer’s Disease by Self-Reported Cancer History in the Alzheimer’s Disease Neuroimaging Initiative

25. A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid

26. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

27. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline

28. Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

29. The relationship between blood‐brain barrier permeability and cerebral blood flow in cognitive impairment

31. The design of Dominantly Inherited Alzheimer Disease Trial of the anti‐tau antibody, E‐2814, on the DIAN‐TU Tau Next Generation Platform

32. Entorhinal thickness: A marker of DHA supplementation efficacy?

33. Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease

34. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (IWG)

35. Correlations between neuropsychological performance and functional measures: Preliminary findings from the novel cognitive and functional measure for Alzheimer’s Disease prevention trials (NoMAD)

37. Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

38. Diversity in Alzheimer's disease drug trials

39. Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trial

40. Impact of Potential Modifications to Alzheimer’s Disease Clinical Trials in Response to Disruption by COVID-19

41. Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy

42. Low-dose ladostigil for mild cognitive impairment

43. Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial

44. A randomized clinical trial to evaluate home‐based assessment of people over 75 years old

45. Evaluation of Medicare Claims Data as a Tool to Identify Dementia

46. Soluble Amyloid-β Consumption in Alzheimer's Disease

47. Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report

48. Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists

49. Value-Generating Exploratory Trials in Neurodegenerative Dementias

50. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

Catalog

Books, media, physical & digital resources